SANA · Sana Biotechnology, Inc.
$3.12
-0.04 (-1.27%)
At close · Jul 22
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that the Company’s current capital resources may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Market Cap
$868.27M
Shares
278.29M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$244.17M
+8.5%
FY2025
Diluted EPS
-$0.96
+17.2%
FY2025
Operating Cash Flow
-$143.83M
+35.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $123.51M | $131.98M | $217.56M | $268.82M | $285.89M | $248.63M | |
| $44.27M | $44.3M | $64.04M | $73.3M | $71.56M | $50.41M | |
| — | $0 | $0 | $0 | $0 | $0 | |
| $248.3M | $250.32M | $272.72M | $293.14M | $272.56M | $356.91M | |
| -$248.3M | -$250.32M | -$272.72M | -$293.14M | -$272.56M | -$356.91M | |
| $2.51M | $2.31M | -$4.51M | -$52K | -$674K | $305K | |
| — | — | — | — | — | -$355.93M | |
| — | $0 | — | — | — | -$7.55M | |
| -$241.99M | -$244.17M | -$266.76M | -$283.26M | -$269.48M | -$355.93M | |
| -$241.99M | -$244.15M | -$266.69M | -$278.99M | -$272.44M | -$357.32M | |
| USD/shares | — | -$0.96 | -$1.16 | -$1.46 | -$1.43 | — |
| USD/shares | — | -$0.96 | -$1.16 | -$1.46 | -$1.43 | — |
| shares | — | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M |
| shares | — | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.58×
EV/EBIT
—
Biotechnology median 26.56×
P/E (TTM)
—
Biotechnology median 7.06×
Key facts
CIK
1770121
CUSIP
799566104
13F (30d)
20 filings
20 filers
Visit website
Investor relations